Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686303 | 0.87 | ANO1 (0.43) | GAAEGFRANO1NPSR1IDO1 | |
| SCHEMBL3734185 | 0.86 | ANO1 (0.51) | GAAEGFRANO1NPSR1IDO1 | |
| SCHEMBL4090969 | 0.84 | EGFR (0.45) | GAAEGFRANO1CYP3A4SMN1; SMN2 | |
| SCHEMBL15050032 | 0.82 | EGFR (0.44) | EGFRANO1MEN1LMNAKMT2A | |
| SCHEMBL14564600 | 0.80 | TSHR (0.44) | GAAEGFRMEN1LMNAMAPT | |
| SCHEMBL3219065 | 0.79 | GAA (0.41) | GAAEGFRANO1IDO1MEN1 | |
| SCHEMBL3207311 | 0.79 | GAA (0.41) | GAAIDO1SMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL4025879 | 0.79 | GAA (0.68) | GAANPSR1MEN1LMNACYP3A4 | |
| SCHEMBL28040264 | 0.78 | MEN1 (0.52) | GAANPSR1IDO1MEN1SLC22A1 | |
| SCHEMBL3186226 | 0.78 | KEAP1 (0.51) | GAAMAPTSMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945932-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2588459-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2588459-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2966064-A1 | PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2588459-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | Allergan, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120165382-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165382-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012003414-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003414-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | CONWAY ELIZABETH ANN | 2009-09-24 | — | — | US | disclosed |
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | CONWAY ELIZABETH ANN | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | PTGER1, PTGDR, PTGIR | GAA 4561/4885EGFR 1217/4885ANO1 3514/4885 |
| US-20120165382-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | GAA 4758/4885EGFR 535/4885ANO1 2377/4885 |
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | GAA 4666/4885EGFR 1739/4885ANO1 4366/4885 |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | PTGER4, PTGER1, GRK4 | GAA 4027/4885EGFR 82/4885ANO1 4023/4885 |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | GAA 4758/4885EGFR 535/4885ANO1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.